Open in interactive viewer → charts, metric popovers & call review

P3 Health Partners Is Profitable on Paper, Insolvent on the Balance Sheet, and Down 59% in 90 Days

A third straight "profitable" quarter rests on $12 million of reconciliations and a liability release; the equity is telling you what it thinks of the remaining $200 million of "value creation."
PIII · Earnings Call · 2026-11-09

The Beat Is a Reconciliation, Again

P3 Health Partners reported $21 million of Adjusted EBITDA for the third quarter, lifted its full-year midpoint to $100 million, and called it a third consecutive profitable quarter. The stock was down roughly 59% over the prior 90 days into the print, and the whole history is a −99% return from a 2021 peak near $572 a share. The market cap is $13.1 million. That gap between the income statement and the tape is the story, and management handed you the explanation in the second paragraph of the CFO's remarks: approximately $7 million of favorable medical margin from the 2025 CMS ACO reconciliation, and approximately $5 million of non-cash income from a liability release tied to the ACO joint venture.

Excluding these and other prior period and non-recurring items, underlying Q3 Adjusted EBITDA was approximately $10 million.

Leif Pedersen · 2026-11-09
So roughly half of a $21 million headline was accounting. This is not a one-off. On the second-quarter call, Leif Pedersen walked through a $54.4 million Adjusted EBITDA figure and subtracted $45 million of favorable prior period development and payer settlement, with “the payer settlement amount was $41 million. And that did not affect revenue. That only affected medical claims expense.” — Leif Pedersen, CFO · 2026-08-10 He described the first half as “$18 million of embedded EBITDA. And $62 million of prior period settlements that came from Q1 and Q2.” — Leif Pedersen, CFO · 2026-08-10 The first quarter was the same shape at smaller scale — “65% of that $17 million is related to change related to prior year -- favorable prior year development of our reserves and about 35% relates to some payer settlements.” — Leif Pedersen, Chief Financial Officer · 2026-05-14 Four quarters, four prior-period lifts. One thing did change: the word itself. settlement was the single highest-momentum keyword on the August call and has since fallen hardest in the company's own momentum history. On this call the same economic event is called a "2025 CMS ACO reconciliation" and a "liability release." Ben Haynor's housekeeping question surfaced the plumbing anyway: “there was about $13 million of medical expense that actually reduced in the quarter related to that portion of the ACO 2025 settlement.” — Leif Pedersen · 2026-11-09

Cost Trend Turns, and Nevada Is the Tell

Aric Coffman's headline claim is real and worth stating plainly: year-to-date Medicare Advantage medical expense is 0.7% below full-year 2025 on a normalized basis, which for a company whose revenue per member is up 18% is genuine margin work.

With peers in our sector reporting medical cost trend of 7% or more, this is a meaningful differentiator for P3.

Aric Coffman · 2026-11-09
But the quarter turned. Medical expense stepped up sequentially, concentrated in outpatient and professional services, with cardiovascular procedures the largest driver. professional services lands as a brand-new high-momentum keyword this quarter — it was not in the top thirty a quarter ago. And the geography is specific: “we did see probably some of those costs increase more in Nevada than probably other markets, which we are looking deep into, especially in regards to that outpatient utilization and some of the professional services in that market.” — Amir Bacchus · 2026-11-09 Nevada is the same market that has been the named problem child in prior calls, so the $200 million opportunity narrative and the recurring problem are in the same state. The disclosure on trend through the year is where I would press. Pedersen offered “we were at 1.7% favorable on a year-over-year basis. Through Q3, that dropped down to 8.7% favorable on a year-over-year basis. Q3 did show some increased pressure on the MedEx side of the business.” — Leif Pedersen · 2026-11-09 A move from +1.7% to +8.7% favorable is not a drop, and it does not square with the prepared remarks. The sign as transcribed points the wrong way; the direction of travel — roughly ten points of deterioration — is what matters, and it is consistent with everything else on the call. This is a sector-wide conversation, not a P3 invention. medical cost trend and pricing discipline were front and center at Oscar Health this week, and Humana opened with a Stars headwind for next year. P3's own recontracting leverage has leaned on Stars performance and burden of illness documentation for several quarters; the quality improvement cited here — nine-point gains in blood pressure and diabetes control, supplemental data submitted at twice last year's pace — is the operating lever that funds the rate conversation.

Shrinking Into Profitability, and the $200 Million Question

Membership is the quiet story. At-risk lives fell to roughly 105,000 from 116,000, a deliberate exit from arrangements that did not clear economic thresholds. Revenue still rose 15% to about $396 million because capitated revenue per member rose 18%. Shrinking the denominator while raising price is a legitimate turnaround move, but it is not growth — and the growth story now rests entirely on “well over 60 mid-sized plans that are in a similar type of situation with a lot of lives” — Aric Coffman · 2026-11-09, plus the 28,000 management services lives that form the at-risk pipeline. Then there is the number the whole equity story hinges on: more than $200 million of identified value creation across payer economics, clinical execution and operating efficiency. It is a fresh keyword and a fresh number, but the framing is recycled — a year ago management was marketing a $120 million to $170 million EBITDA opportunity set, and the same three buckets. Pedersen was candid that it is “a multi-year realization into the P&L. That timing's going to depend on execution” — Leif Pedersen · 2026-11-09, with clinical execution the largest piece and operating efficiency the smallest. Against a $13 million market cap, $200 million of self-identified value is either the cheapest option in healthcare or a number the market has already discounted to zero. The fundamentals explain the skepticism. Through the second quarter — the last period actually filed — total revenue was $386 million with free cash flow of −$63 million, and free cash flow less stock comp sat at −16.3% of revenue. Effective net cash was negative $98 million at that point, and liabilities reached 121% of assets earlier in 2026 before easing to 79%. The $44 million of quarter-end cash has to fund a business that consumed $29 million and $63 million in the last two reported quarters. Price to revenue is 0.1x. That is not a mistrust of the medical margin work — the utilization management numbers are genuinely good, with the inpatient-to-observation conversion moving from 24% to 34% and outpatient prior authorization avoidance up 68%. It is a statement that the enterprise value belongs to the payers, the ACO joint venture and the balance sheet, not to the common holder.

What to Watch

The 2027 guidance — promised for early next year, along with the timing and earnings contribution of the $200 million — is now the whole thesis. Watch two things: whether the glide path in Nebraska and any successor plan wins arrive before cash does, and whether the fourth quarter arrives without another "reconciliation." Three consecutive profitable quarters built substantially on prior-period true-ups is a pattern, not a streak, and the tape has already priced it that way.